Dame Emma Walmsley has been CEO at GSK since 2017. This week has kicked off with the unexpected news that Emma Walmsley is standing down as chief executive of GSK after eight years, to be replaced by ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...